REVIEW PAPER
Cardiovascular risk assessment in rheumatoid arthritis – controversies and the new approach
Submission date: 2016-05-25
Final revision date: 2016-06-17
Acceptance date: 2016-06-21
Online publication date: 2016-07-18
Publication date: 2016-06-30
Reumatologia 2016;54(3):128-135
KEYWORDS
TOPICS
ABSTRACT
The current methods of cardiovascular (CV) risk assessment in the course of inflammatory connective tissue diseases are a subject of considerable controversy. Comparing different methods of CV risk assessment in current rheumatoid arthritis (RA) guidelines, only a few of them recommend the use of formal risk calculators. These are the EULAR guidelines suggesting the use of SCORE and the British Society for Rheumatology guidelines performed in collaboration with NICE preferring the use of QRISK-2. Analyzing the latest American and British reports, two main concepts could be identified. The first one is to focus on risk calculators developed for the general population taking into account RA, and the calculator that might fulfill this role is the new QRISK-2 presented by NICE in 2014. The second concept is to create RA-specific risk calculators, such as the Expanded Cardiovascular Risk Prediction Score for RA. In this review we also discuss the efficiency of a new Pooled Cohort Equation and other calculators in the general and RA population.
REFERENCES (58)
1.
Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-945.
2.
Nurmohamed M, Herslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015; 11: 693-704.
3.
Wilson P, Abbott R, Castelli W. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737-741.
4.
Smith JD. Myeloperoxidase, inflammation, and dysfunctional HDL. J Clin Lipidol 2010; 5: 382-388.
5.
Głuszko P, Filipowicz-Sosnowska A, Rupiński R. Lipid profile in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs. Reumatologia 2014; 52: 120-128.
6.
Dursunoğlu D, Evrengül H, Polat B. Lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-245.
7.
Öhman M, Öhman ML, Wållberg-Jonsson. The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis. Scand J Rheumatol 2014; 43: 259-264.
8.
Sattar N, McCarey DW, Capell H. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-2963.
9.
Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum 2015; 67: 1449-1455.
10.
Arts EE, Fransen J, den Broeder AA, et al. Extended report The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015; 74: 998-1003.
11.
Smolen JS, Aletaha D. Scores for all seasons: SDAI and CDAI. Clin Exp Rheumatol 2014; 32: 75-79.
12.
Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis:a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-2299.
13.
Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis 2016; 75: 341-347.
14.
Goodson N, Marks J, Lunt M, et al. Cardiovascular admissions and mortality in an incepcion cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-1601.
15.
Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA.
17.
Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307.
18.
Kisiel B, Kruszewski R, Juszkiewicz A, et al. Methotrexate, cyclosporine A, and biologics protect against atherosclerosis in rheumatoid arthritis. J Immunol Res 2015; 2015: 759610.
19.
Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55: 531-536.
20.
Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 3790-3798.
21.
Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015; 10(2): e0117952.
22.
Davis JM, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007; 56: 820-830.
23.
Kaplan MJ. Cardiovascular complications of rheumatoid arthritis – assessment, prevention and treatment. Rheum Dis Clin North Am 2010; 36: 405-426.
24.
Roubille C, Richer V, Starnino T. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-489.
25.
Głuszko P, Bielińska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors? Pol Arch Med Wewn 2009; 119: 231-235.
26.
Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014; 73: 1515-1521.
27.
Nurmohamed M. Speaker Presentations Eular Recommendation Update on Cardiovascular Disease in RA. Ann Rheum Dis 2015; 74 (suppl 2): 9 Available at pathlms.com/eular/events/363/thumbnails_video_presentations/13056.
28.
van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011; 40: 389-397.
29.
Turesson C, O’Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62-67.
30.
Peters MJ, Symmons DP, McCarey D, et al. Recommendations EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-331.
31.
Arts EE, Popa CD, den Broeder AA, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis 2016; 75: 674-680.
32.
Purcarea A, Sovaila S, Gheorghe A, et al. Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis? J Med Life 2014; 7: 461-467.
33.
Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
34.
Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-934.
35.
Myasoedova E, Crowson CS, Kremers HM. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482-487.
36.
Arts EEA, Popa C, Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis.. Ann Rheum Dis 2015; 74: 668-674.
37.
Corrales A, Parra JA, González-Juanatey C, et al. Cardiovascular risk stratification in rheumatic diseases:carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1764-1770.
38.
Głuszko P, Bonek K. Statins in rheumatology: revisited. Reumatologia 2014; 52: 351-353.
39.
González-Gay MA, González-Juanatey C, Llorca J. Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom? Ann Rheum Dis 2012; 71: 796-798.
40.
Hippisley-Cox J, Coupland C, VinogradovaY, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336: 1475-1482.
41.
Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: 1-45.
42.
Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA Guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311: 1416-1423.
43.
Tournadre A, Tatar Z, Pereira B, et al. Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. Int J Cardiol 2015; 183: 149-154.
44.
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382: 1762-1765.
45.
Greenland P, Lauer MS. Cholesterol lowering in 2015 still answering questions about how and in whom. JAMA 2015; 314: 127-128.
46.
Solomon DH, Greenberg J, Curtis JR, et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheum 2015; 67: 1995-2003.
47.
Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women the Reynolds Risk Score. JAMA 2007; 297: 611-619.
48.
Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118: 2243-2251.
49.
Pencina MJ, D’Agostino BD, Lason MG, et al. Predicting the 30-Year Risk of Cardiovascular Disease The Framingham Heart Study. Circulation 2009; 119: 3078-3084.
50.
Ralph B, D’Agostino S, Ramachandran S, et al. General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation 2008; 117: 743-753.
51.
Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8: R186.
52.
Mahoney LT, Burns TL, Stanford W, et al. Usefulness of the Framingham risk score and body mass index to predict early coronary artery calcium in young adults (Muscatine Study). Am J Cardiol 2001; 88: 509-515.
53.
Chung CP, Oeser A, Avalos I, et al. Cardiovascular risk scores underestimate the presence of subclinical coronary-artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15: 562-569.
54.
Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997; 96: 2128-2136.
55.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 2002; 105: 310-315.
56.
Arts EEA. Transatlantic cardiovascular risk calculator for rheumatoid arthritis (ATACC-RA). Ann Rheum Dis 2014; 73: 123-124.
57.
Heslinga S, Van den Oever, I, Van Sijl A, et al. Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation. BMC Musculoskeletal Disorders 2015; 16: 1-8.
58.
Sattar N. How to assess the CVD risk in the individual patient? Ann Rheum Dis 2016 SP0012. DOI: 10.1136/annrheumdis-2016-eular.6435.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
